RVTY news

Latest 1 stories · newest Aug 4, 2026

RVTY

Revvity reports strong second-quarter results and raises full-year guidance.

Revvity reported a 4% pro forma revenue growth and raised full-year guidance for 2026, while entering a definitive agreement to divest its China immunodiagnostics business.

Guidance Aug 4, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RVTY feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RVTY/newsSTART FREE